Literature DB >> 12234858

In vitro activity of the new oxazolidinone AZD2563 against Enterococci.

G M Eliopoulos1, C B Wennersten, R C Moellering.   

Abstract

The activity of a new oxazolidinone antimicrobial, AZD2563, was assessed against >500 clinical isolates of enterococci representing six species. All isolates, including those resistant to other antibiotic classes, were inhibited by AZD2563 at concentrations </=2 micro g/ml, except for four strains resistant to linezolid. In most cases, AZD2563 was twofold more active than linezolid against enterococci.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12234858      PMCID： PMC128778          DOI： 10.1128/AAC.46.10.3273-3275.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  4 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  R C Moellering
Journal:  Clin Infect Dis       Date:  1998-05       Impact factor: 9.079

2.  Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin.

Authors:  G M Eliopoulos; C B Wennersten; H S Gold; T Schülin; M Souli; M G Farris; S Cerwinka; H L Nadler; M Dowzicky; G H Talbot; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

3.  In vitro activities in new oxazolidinone antimicrobial agents against enterococci.

Authors:  G M Eliopoulos; C B Wennersten; H S Gold; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

Review 4.  Oxazolidinones: a review.

Authors:  D I Diekema; R N Jones
Journal:  Drugs       Date:  2000-01       Impact factor: 11.431
  4 in total
  2 in total

1.  In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria.

Authors:  Dongeun Yong; Jong Hwa Yum; Kyungwon Lee; Yunsop Chong; Sung Hak Choi; Jae Keol Rhee
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

2.  Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea.

Authors:  Jong Hwa Yum; Sung Hak Choi; Dongeun Yong; Yunsop Chong; Weon Bin Im; Dong-Kwon Rhee; Kyungwon Lee
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.